BRIEF—Mundipharma to distribute Grünenthal's analgesic Tramal in China

Privately-held firms Grünenthal and Mundipharma have agreed a licensing and distribution deal for the former’s analgesic Tramal (tramadol) in China.

From May, UK-based Mundipharma will be responsible for selling the well-established treatment for moderate to severe pain in the country.

This will include sustained release tablets and immediate release capsules, as well as an intravenous formulation used for post-operative pain, which is delivered via a patient-controlled device (PCIA).

Mundipharma chief executive Raman Singh said: "The addition of Tramal to our portfolio reinforces Mundipharma's position as the international leader in advancing appropriate cancer-related pain relief in China."

"PCIA is an advanced option for medical professionals to treat patients suffering from moderate to severe pain. We are pleased to extend our relationship with Grünenthal to advance the treatment of patients in China, where there remains an unmet patient need."